P&G Intrinsa Gets No Satisfaction; Potential Risks Outweigh Sexual Benefits
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Reproductive Health Drugs Advisory Committee votes unanimously Dec. 2 that current efficacy and safety data for the female sexual dysfunction therapy do not support approval. Committee recommends completion of safety studies in pre- and postmenopausal women prior to approval.
You may also be interested in...
Intrinsa Advisory Cmte. Decision Should Not Affect Dapoxetine, PPD Says
An FDA advisory committee's recommendation against approval of Procter & Gamble's testosterone patch Intrinsa should not impact Johnson & Johnson's premature ejaculation therapy dapoxetine, PPD says
Intrinsa Advisory Cmte. Decision Should Not Affect Dapoxetine, PPD Says
An FDA advisory committee's recommendation against approval of Procter & Gamble's testosterone patch Intrinsa should not impact Johnson & Johnson's premature ejaculation therapy dapoxetine, PPD says
P&G Intrinsa Need For Longer-Term Safety Data To Be Examined By Reproductive Cmte.
FDA will ask committee whether Intrinsa testosterone patch needs more safety data in women receiving estrogen prior to approval. Procter & Gamble is proposing a pharmacovigilance study to follow emerging adverse events with the female sexual dysfunction drug.